Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Whole-Brain Radiotherapy 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1Leiomyosarcoma 1Fallopian Tube Neoplasms 1Extensive Small Cell Lung Cancer 1Endometrial Neoplasms 1Carcinoma, Hepatocellular 1Advanced Renal Cancer 1Advanced Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 1aumolertinib 1anlotinib 1abivertinib 1Radiosurgery 1Pemetrexed 1Gefitinib 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Non-small Cell Lung Cancer × anlotinib × Clear all
NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Qianfoshan Hospital

Phase 3 Recruiting
98 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡